PARP1 and cancer: Pre-clinical data has shown that DNA-PKcs inhibitors could re-sensitize taxane-resistant cells and restore sensitivity to multiple genotoxic agents, including topoisomerase inhibitors and platinum drugs, and ongoing clinical trials are testing DNA-PKcs inhibitors with RT, PARP inhibitors, and CHK1 inhibitors in a variety of cancer types [37,186].